Clinical Trials Logo

Depressive Disorder, Major clinical trials

View clinical trials related to Depressive Disorder, Major.

Filter by:

NCT ID: NCT03193398 Recruiting - Clinical trials for Major Depressive Disorder

BTRX-246040 Administered Once Daily to Patients With Major Depressive Disorder

Start date: June 12, 2017
Phase: Phase 2
Study type: Interventional

This study will determine the efficacy, safety, and tolerability of a once-daily (QD) dose of up to 80 mg of BTRX-246040 for 8 weeks in participants with MDD.

NCT ID: NCT03191994 Recruiting - Clinical trials for Major Depressive Disorder

Impact of an Eight Week Exercise Intervention in Treating Major Depressive Disorder

Start date: January 2, 2014
Phase: N/A
Study type: Interventional

To investigate the impact of a structured eight week exercise intervention as an add-on therapy in treating Major Depressive Disorder. Using behavioural techniques and neuroimaging to measure changes in brain function following an exercise intervention in people with clinical depression. By correlating changes in the hippocampus with changes in HPA axis hormones, inflammatory cytokines and growth factors it is possible to determine which of the biochemical markers is most predictive of improved neural function.

NCT ID: NCT03190772 Not yet recruiting - Clinical trials for Major Depressive Episode

The Role of Expectations in the Pharmacological Treatment of Depression - An Experimental Investigation

Start date: July 1, 2017
Phase: N/A
Study type: Interventional

The study aimes at identifying whether positive expectations have an impact on the way depressive participants experience emotions in the form of sadness.

NCT ID: NCT03188185 Recruiting - Clinical trials for Major Depressive Disorder

A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)

Start date: June 12, 2017
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy, safety, and tolerability of adjunctive ALKS 5461 in adults who have treatment refractory MDD.

NCT ID: NCT03187093 Recruiting - Clinical trials for Major Depressive Disorder

Cognitive Dysfunction in MDD Patients

Start date: October 2016
Phase: Phase 4
Study type: Interventional

Major Depressive Disorder (MDD) is one of the most prevalent mental diagnosis within the worldwide population. Although there is evidence about relationship between MDD and cognitive dysfunction, still the correlations between biomarkers and the severity of the disorder or the level of cognitive dysfunction need further research. Therefore, the aim of the study is to determine such relationships in Ukrainian population.

NCT ID: NCT03185819 Not yet recruiting - Clinical trials for Depressive Disorder, Major

Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide

Start date: August 14, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy of a single (first) dose of 3 fixed doses of intranasal esketamine {28 milligram (mg), 56 mg, and 84 mg} compared with psychoactive placebo (oral midazolam) in rapidly reducing the symptoms of major depressive disorder (MDD) including suicidal ideation in participants 12 to less than 18 years of age who are assessed to be at imminent risk for suicide.

NCT ID: NCT03183505 Not yet recruiting - Clinical trials for Major Depressive Disorder

Comparison of Anyu Peibo With Placebo in Treatment of MDD,Ⅱb

Start date: June 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of Anyu Peibo Capsule comparing with placebo in the treatment of Chinese Patients with Depression. And to provide some scientific evidence for protocol designing in following phase Ⅲ clinical trial.

NCT ID: NCT03181529 Not yet recruiting - Clinical trials for Major Depressive Disorder

Effects of Psilocybin in Major Depressive Disorder

Start date: June 2017
Phase: Phase 2
Study type: Interventional

The proposed pilot study will assess whether people with major depressive disorder experience psychological and behavioral benefits and/or harms from psilocybin. This study will investigate acute and persisting effects of psilocybin on depressive symptoms and other moods, attitudes, and behaviors. Our primary hypothesis is that psilocybin will lead to rapid and sustained antidepressant response, as measured with standard depression rating scales.

NCT ID: NCT03175068 Not yet recruiting - Clinical trials for Major Depressive Disorder

Transdiagnostic Brain-Behavior Profiling to Enhance Cognitive Behavioral Therapy Response

Start date: July 2017
Phase: N/A
Study type: Interventional

Many patients with Major Depressive Disorder (MDD) and generalized Social Anxiety Disorder (gSAD) are treated with cognitive behavioral therapy (CBT) but few have meaningful improvement. MDD and gSAD are diseases of brain dysfunction that manifest as impaired emotion regulation; CBT teaches emotion regulation strategies but how it works in the brain remains largely unknown. Individual differences in brain function related to emotion regulation may make some patients better suited for CBT and CBT may remedy the brain dysfunction that underlies these disorders. This project will compare CBT with a placebo psychotherapy (i.e., supportive therapy) in MDD and gSAD to test, validate, and refine brain-based markers and examine mechanisms of change to examine how CBT works and for whom.

NCT ID: NCT03170362 Not yet recruiting - Major Depression Clinical Trials

PRIME Care (PRecision Medicine In MEntal Health Care)

PRIME Care
Start date: June 15, 2017
Phase: N/A
Study type: Interventional

The focus of this application is on the impact of providing depressed Veterans and their providers with the results of pharmacogenetic (PGx) testing for psychotropic medications. The project focuses on whether and how patients and providers use genetic test results given to them at the time an antidepressant is to be initiated to treat Major Depressive Disorder (MDD) and whether use of the test results improves patient outcomes. MDD is one of the most common conditions associated with military service and combat exposure, increases suicide risk, and worsens the course of common medical conditions, making it a leading cause of functional impairment and mortality. Validation of a PGx test to personalize the treatment of MDD represents an important opportunity to improve the healthcare of Veterans.